| Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma KM Field, J Simes, AK Nowak, L Cher, H Wheeler, EJ Hovey, CSB Brown, ... Neuro-oncology 17 (11), 1504-1513, 2015 | 152 | 2015 |
| Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy–results from the randomised phase II ETOP/IFCT 4-12 … S Peters, JL Pujol, U Dafni, M Dómine, S Popat, M Reck, J Andrade, ... Annals of Oncology 33 (1), 67-79, 2022 | 58 | 2022 |
| Preferences for immunotherapy in melanoma: a systematic review A Livingstone, A Agarwal, MR Stockler, AM Menzies, K Howard, ... Annals of Surgical Oncology 27, 571-584, 2020 | 49 | 2020 |
| A randomized phase II study of carboplatin and bevacizumab in recurrent glioblastoma multiforme (CABARET). KM Field, J Simes, H Wheeler, EJ Hovey, AK Nowak, L Cher, C Brown, ... Journal of Clinical Oncology 31 (15_suppl), 2017-2017, 2013 | 31 | 2013 |
| Culturally and linguistically diverse patient participation in glioma research Z Lwin, A Broom, R Cosman, A Livingstone, K Sawkins, P Good, E Kirby, ... Neuro-oncology practice 1 (3), 101-105, 2014 | 24 | 2014 |
| Continuing or ceasing bevacizumab beyond progression in recurrent glioblastoma: an exploratory randomized phase II trial EJ Hovey, KM Field, MA Rosenthal, EH Barnes, L Cher, AK Nowak, ... Neuro-Oncology Practice 4 (3), 171-181, 2017 | 21 | 2017 |
| Cost-effectiveness of extracorporeal cardiopulmonary resuscitation for adult out-of-hospital cardiac arrest: a systematic review D Addison, E Cheng, P Forrest, A Livingstone, RL Morton, M Dennis Resuscitation 178, 19-25, 2022 | 19 | 2022 |
| Physician-patient communication of costs and financial burden of cancer and its treatment: a systematic review of clinical guidelines A Agarwal, A Livingstone, DJ Karikios, MR Stockler, PJ Beale, RL Morton BMC cancer 21, 1-10, 2021 | 19 | 2021 |
| Neuro‐oncology practices in Australia: A Cooperative Group for Neuro‐Oncology patterns of care study JY Chen, E Hovey, M Rosenthal, A Livingstone, J Simes Asia‐Pacific Journal of Clinical Oncology 10 (2), 162-167, 2014 | 17 | 2014 |
| Is routine distal clavicle resection necessary in rotator cuff repair surgery? A systematic review and meta-analysis A Livingstone, R Asaid, AK Moaveni Shoulder & Elbow 11 (1_suppl), 39-45, 2019 | 14 | 2019 |
| Continuing or ceasing bevacizumab at disease progression: Results from the CABARET study, a prospective randomized phase II trial in patients with recurrent glioblastoma. EJ Hovey, KM Field, M Rosenthal, AK Nowak, L Cher, H Wheeler, ... Journal of Clinical Oncology 33 (15_suppl), 2003-2003, 2015 | 14 | 2015 |
| Validating self-report and proxy reports of the Dexamethasone Symptom Questionnaire-Chronic for the evaluation of longer-term corticosteroid toxicity M Agar, ES Koh, E Gibbs, EH Barnes, E Hovey, A Livingstone, K Sawkins, ... Supportive Care in Cancer 24, 1209-1218, 2016 | 13 | 2016 |
| Should I have adjuvant immunotherapy? An interview study among adults with resected stage 3 melanoma and their partners A Livingstone, D Milne, K Dempsey, DM Muscat, AM Menzies, K Howard, ... The Patient-Patient-Centered Outcomes Research 14 (5), 635-647, 2021 | 12 | 2021 |
| CABARET/COGNO investigators Continuing or ceasing bevacizumab beyond progression in recurrent glioblastoma: an exploratory randomized phase II trial EJ Hovey, KM Field, MA Rosenthal, EH Barnes, L Cher, AK Nowak, ... Neurooncol Pract 4 (3), 171-181, 2017 | 7 | 2017 |
| Adjuvant immunotherapy recommendations for stage III melanoma: physician and nurse interviews A Livingstone, K Dempsey, MR Stockler, K Howard, GV Long, MS Carlino, ... BMC cancer 21, 1-9, 2021 | 6 | 2021 |
| NIVORAD: A randomised phase 2 trial of nivolumab and stereotactic ablative body radiotherapy in advanced non-small cell lung cancer, progressing after first or second line … P Mitchell, S Siva, PS Kok, K O'Byrne, A Yeung, A Livingstone, ... Journal of Clinical Oncology 35 (15_suppl), TPS9097-TPS9097, 2017 | 5 | 2017 |
| Discussing the costs and financial burden of cancer and its treatment: a systematic review of clinical guidelines A Agarwal, A Livingstone, DJ Karikios, MR Stockler, PJ Beale, RL Morton | 2 | 2021 |
| P2. 03-044 OSCILLATE-Phase 2 Trial of Alternating Osimertinib with Gefitinib in Patients with EGFR-T790M Mutation Positive Advanced NSCLC B Solomon, P Kok, A Livingstone, S Yip, C Brown, S Dawson, S Wong, ... Journal of Thoracic Oncology 12 (11), S2144, 2017 | 2 | 2017 |
| P2. 06-025 DREAM-A Phase 2 Trial of DuRvalumab with First Line chEmotherApy in Mesothelioma with a Safety Run In: Topic: Mesothelioma and SCLC A Nowak, PS Kok, A Livingstone, WJ Lesterhuis, S Yip, M Donoghoe, ... Journal of Thoracic Oncology 12 (1), S1086-S1087, 2017 | 2 | 2017 |
| Preferences for adjuvant immunotherapy in patients with resected stage III melanoma: A discrete choice experiment. A Livingstone, AM Menzies, K Howard, MR Stockler, RL Morton Journal of Clinical Oncology 40 (16_suppl), 9558-9558, 2022 | 1 | 2022 |
Martin StocklerNHMRC Clinical Trials Centre, University of Sydney在 sydney.edu.au 的电子邮件经过验证
